Under a tenth of individuals who could benefit from weight-loss injections including Wegovy are able to get them, warns the global health agency as it releases its first guidance on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging broader and more equitable access to these injectable treatments.
Based on projections, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"The new guidelines acknowledges that obesity is a lifelong illness that can be addressed with holistic and lifelong care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are major obstacles to widespread availability to the treatments that can help people shift considerable weight, explains the agency.
Skinny Jab Supply Crisis
Despite the present most optimistic case, the production of these medications would only suffice for about 100 million people – less than 10% of the global need, per the health organization.
The guideline urges countries and companies to increase availability, by strategies including licensing agreements.
The intellectual property rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple countries in 2026.
How Weight-Loss Jabs Function
GLP-1 drugs imitate a body's own hormone to delay gastric emptying, suppress the appetite and enhance feelings of fullness so individuals consume fewer calories.
Individuals usually start to lose weight within a few weeks of starting on the once-weekly jabs.
Studies suggests patients may put most of the weight back on after a year of discontinuing the drug, as their typical food cravings return.
To be above a healthy weight elevates your likelihood for developing diseases, including diabetes, cardiovascular issues, stroke, and some cancers.
Obesity impacts individuals in all nations and was associated with millions of deaths worldwide in 2024, as per the health agency.
